ArticleTranslational cancer research2025
Extracellular vesicles isolated from SphK1 inhibitor SKI II-medium restrain the migration of colorectal cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer is a chronic disease particularly detrimental to human health. Although there have been many studies on colorectal cancer and extracellular vesicles (EVs), it is unknown whether SKI II, an inhibitor of sphingosine kinase 1 (SphK1), uses EVs as transporters to inhibit colorectal cancer migration. This research aimed to investigate whether EVs, which were isolated from SphK1 inhibitor SKI II-medium, affected on E-cadherin and vimentin and the cell migration of colorectal cancer cells. Methods: EVs were extracted from RKO cells using an exosome extraction and purification kit, and the extracted EVs were identified to evaluate whether the EVs extracted by this kit met the experimental requirements. Results: Compared with the control group, after GW4869 treatment, E-cadherin was increased, vimentin was decreased, and the number of migrating cells was decreased. After Conclusions: EVs isolated from SphK1 inhibitor SKI II-medium affect E-cadherin and vimentin expression in colorectal cancer and inhibit cell migration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.